Abstract
INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory disease. HS patients develop painful subcutaneous nodules, primarily in the intertriginous regions. Early diagnosis is crucial to initiate appropriate treatment, which may prevent disease progression. The cost of treatment increases with disease severity. Studies have found a considerable diagnostic delay in HS. Screening programs may reduce diagnostic delay and allow for better utilization of resources.
METHODS: Arguments for implementing an HS screening program were explored based on the 10 WHO criteria for implementing screening programs.
RESULTS: HS is an important health problem due to its prevalence and the adverse effects of the disease. Facilities for treatment and diagnosis exist, and the validated screening questionnaire is considered acceptable to the population. HS patients should be seen by a dermatologist and treated accordingly. Medical expenses increase with disease severity, and finding patients with early-stage HS is considered cost-effective.
CONCLUSIONS: We consider a screening program as valuable for public healthcare. Patients can avoid extensive surgery or treatment with biologics if disease progression is prevented, and this will reduce medical expenses for the public healthcare system. Politicians should consider implementing a screening program for HS.
| Original language | English |
|---|---|
| Journal | Acta Dermatovenerologica Alpina, Panonica et Adriatica |
| Volume | 27 |
| Pages (from-to) | 115-120 |
| ISSN | 1318-4458 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- Anti-Infective Agents/therapeutic use
- Delayed Diagnosis/statistics & numerical data
- Denmark
- Disease Progression
- Female
- Hidradenitis Suppurativa/diagnosis
- Humans
- Male
- Mass Screening/organization & administration
- Needs Assessment